表 3.

西维来司他钠治疗与COVID-19相关ARDS重症患者临床结局之间的关系

Association between sivelestat sodium administration and clinical outcomes ofARDS patients with COVID-19

Clinical outcomes	Total	Control group	Sivelestat group	P	HR (95% CI)
PSM; HR: Hazard ratio; CI: Confidence interval; ICU: Intensive care unit. aCox regression was used for estimating the impact of Sivelestat sodium use on mortality outcomes adjusting for confounding variables selected based on P < 0.05 in univariate analysis and potential confounders judged by the clinical expertise of our team, including age, gender, APACHE Ⅱ score, mechanical ventilation, CRRT, CRP, PCT, IL-6. bLinear regression was used to evaluate the association between Sivelestat sodium use and length of stay. HR was calculated using the formula HR=eβ.
Before PSM	n=199	n=164	n=35
Survival rate [n (%)]a	103 (51.8)	88 (53.7)	15 (42.9)	0.81	1.08 (0.56, 2.10)
Length of ICU stayb	10.11 [5.15, 18.26]	10.00 [4.93, 16.30]	14.27 [7.80, 25.44]	0.22	1.57 (0.87, 2.57)
Length of hospital stayb	19.76 [11.14, 31.65]	17.53 [10.90, 32.20]	24.61 [13.75, 30.94]	0.2	1.42 (0.76, 1.73)
After PSM	n=105	n=70	n=35
Survival rate [n (%)]a	42 (40.0)	27 (38.6)	15 (42.9)	0.36	1.36 (0.70, 2.62)
Length of ICU stayb	12.91 [7.01, 21.63]	12.84 [6.96, 20.55]	14.27 [7.80, 25.44]	0.39	1.68 (0.49, 2.45)
Length of hospital stayb	21.02 [10.91, 33.35]	19.71 [10.76, 33.36]	24.61 [13.75, 30.94]	0.68	1.20 (0.63, 2.35)